home / stock / rhhby / rhhby quote
Last: | $39.27 |
---|---|
Change Percent: | 0.33% |
Open: | $39.21 |
Close: | $39.27 |
High: | $39.36 |
Low: | $39.11 |
Volume: | 2,641,410 |
Last Trade Date Time: | 07/19/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$39.27 | $39.21 | $39.27 | $39.36 | $39.11 | 2,641,410 | 07-19-2024 |
$39.34 | $39.1 | $39.34 | $39.44 | $39.03 | 2,344,213 | 07-18-2024 |
$39 | $38.99 | $39 | $39.16 | $38.69 | 6,014,502 | 07-17-2024 |
$36.27 | $35.96 | $36.27 | $36.31 | $35.95 | 1,078,937 | 07-16-2024 |
$35.96 | $36.54 | $35.96 | $36.55 | $35.92 | 3,116,965 | 07-15-2024 |
$35.69 | $35.62 | $35.69 | $35.79 | $35.62 | 1,962,122 | 07-12-2024 |
$35.16 | $35.18 | $35.16 | $35.34 | $35.114 | 586,793 | 07-11-2024 |
$34.8 | $34.3 | $34.8 | $34.84 | $34.2845 | 1,951,016 | 07-10-2024 |
$34.25 | $34.15 | $34.25 | $34.29 | $34.028 | 1,298,172 | 07-09-2024 |
$33.89 | $34.1 | $33.89 | $34.1 | $33.76 | 4,178,923 | 07-08-2024 |
$34.03 | $34.1 | $34.03 | $34.12 | $33.85 | 1,260,510 | 07-05-2024 |
$34.11 | $34.28 | $34.11 | $34.34 | $34.1 | 1,496,995 | 07-04-2024 |
$34.11 | $34.28 | $34.11 | $34.34 | $34.1 | 1,496,995 | 07-03-2024 |
$34.43 | $34.3 | $34.43 | $34.512 | $34.29 | 1,649,918 | 07-02-2024 |
$34.64 | $34.545 | $34.64 | $34.84 | $34.53 | 1,329,283 | 07-01-2024 |
$34.67 | $34.75 | $34.67 | $34.82 | $34.56 | 1,218,740 | 06-28-2024 |
$34.91 | $34.92 | $34.91 | $35.02 | $34.81 | 2,685,152 | 06-27-2024 |
$34.66 | $34.79 | $34.66 | $34.91 | $34.63 | 3,588,807 | 06-26-2024 |
$35.57 | $35.42 | $35.57 | $35.65 | $35.32 | 2,022,190 | 06-25-2024 |
$35.71 | $35.56 | $35.71 | $35.79 | $35.53 | 2,652,885 | 06-24-2024 |
News, Short Squeeze, Breakout and More Instantly...
Roche Holding Ltd ADR Company Name:
RHHBY Stock Symbol:
OTCMKTS Market:
Roche Holding Ltd ADR Website:
2024-07-22 05:59:00 ET Both Pfizer (NYSE: PFE) and Roche Holdings (OTC: RHHBY) rank among the world's most powerful pharmaceutical companies. Yet neither is actively competing in the all-important market for weight loss drugs, which is currently being split between the likes...
– Two-year Phase III data presented at ASRS 2024 show Susvimo’s potential as an alternative to eye injections to treat diabetic macular edema (DME) and diabetic retinopathy (DR) – – Safety data were consistent with the known safety profile for Susvimo in people...
2024-07-17 13:21:54 ET Shares of Swiss pharmaceuticals company Roche Holding (OTC: RHHBY) soared 7% through 11:55 a.m. ET Wednesday on positive data from phase 1 clinical trials of its new weight loss drug CT-996. But good news for Roche is bad news for the companies that no...